1083 patents
Utility
CD3 Binding Antibodies
18 Jan 24
The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
Filed: 18 Jan 23
Utility
Agonistic ANTI-IL-2R Antibodies and Methods of Use
18 Jan 24
Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.
Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
Filed: 29 Aug 23
Utility
bsza gd082x8c0a1hgn9lqiq40y3gb
16 Jan 24
In a method for imaging a container holding a sample, the container is illuminated with a laser sheet of a first color, and one or more images of the container are capturing by a first imager configured to filter out colors other than the first color.
Thomas Clark Pearson, Graham F. Milne, Dmitry Fradkin, Erwin Freund
Filed: 27 Dec 22
Utility
67pbnh9th50qen i7heg5iu6f66tb06cka0ke8gxiwal80p
16 Jan 24
Viengkham Malathong, Venkat Reddy Mali, Darren J. McMurtrie, Sreenivas Punna, Howard S. Roth, Rajinder Singh, Ju Yang, Penglie Zhang
Filed: 9 Jul 20
Utility
wxiyl76dfuk7je8k2przsjf5hclz y5wfzxn12syhjk51dimxwt
16 Jan 24
Methods and compositions for treating ovarian cancer in a human patient with ascites by administering a therapeutically effective amount of an Ang2 inhibitor in combination with a taxane.
Bruce Allen Bach, Florian Vogl
Filed: 3 Nov 20
Utility
88a35 pi6wbfg5i049q0swux
16 Jan 24
A device and method for drug delivery includes a casing for housing a drug storage container, the container including a dose delivery member, at least a portion of the dose delivery member extending through an opening in the casing; a guard movable relative to the casing between extended and retracted positions; an interference arrangement for providing selected threshold of resistance to movement of the guard from the extended position to the retracted position during insertion of the dose delivery member into body tissue at an injection site, the arrangement having a first member and a second member, the first and second members engaging one another to retain the guard in the extended position, one of the first and second members moving if the selected threshold of resistance is exceeded to allow the members to slide past one another to allow the guard to move into the retracted position.
Scott R. Gibson, Sheldon Moberg
Filed: 18 Nov 20
Utility
kwfnx6yu42ci3oyudkai8zk80sgwsjt20iygd6fc80a23xf
16 Jan 24
Anti-CD22 heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B cell disorders that are characterized by the expression of CD22.
Shelley Force Aldred, Wim van Schooten, Heather Anne N. Ogana, Laura Marie Davison, Katherine Harris, Udaya Rangaswamy, Nathan D. Trinklein
Filed: 21 Dec 18
Utility
q2ucw1xymbwps485z8m27dguw78jz1bgm4eb6cah zzkh
16 Jan 24
Disclosed herein are aqueous pharmaceutical formulations comprising denosumab or another human anti-RANKL monoclonal antibody or portion thereof, and characteristics of pH, buffer systems, and amino acid aggregation inhibitors.
Stephen Robert Brych, Lyanne M. Wong, Jaymille Fallon, Monica Michelle Goss, Jian Hua Gu, Pavan K. Ghattyvenkatakrishna
Filed: 18 Nov 21
Utility
vmexjjuk665n2pia yxo8sivuimmj9lgo
16 Jan 24
The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high.
Matthias Schneider, Sabine Blum, Renee Jeanne Mendell-Harary, Daniel J. Freeman, Robert Allen Beckman, Xiaoping Jin, Kimio Yonesaka, Kazuhiko Nakagawa
Filed: 21 Aug 19
Utility
l1wa4h0ik 3rnhqnd5dlf74qolu19
11 Jan 24
Described herein are materials and methods for protein production and analysis.
Sreekanth SURAVAJJALA, Jennifer Lynn LIPPENS
Filed: 1 Nov 21
Utility
7laewa584dxnm4dibtvy3 mnu2byiswj6pne525s74v73ye2
11 Jan 24
There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.
Jeonghoon SUN, Jason Charles O'NEILL, Randal R. KETCHEM, Randy Ira HECHT, Edward J. BELOUSKI, Mark Leo MICHAELS
Filed: 28 Aug 23
Utility
h8cdf932tvsbqtiqf62gqg53hhfmddbugi02gdu3skstruipb1
11 Jan 24
The present invention provides to a antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell.
Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, M. Shawn Jeffries, Chadwick Terence King, Brian Mingtung Chan, Peter Kufer, Ralf Lutterbüse, Tobias Raum, Patrick Hoffmann, Doris Rau, Roman Kischel, Bryan Lemon, Holger Wesche
Filed: 19 Sep 22
Utility
ycrtfqss4wolmd39hgrgtuj6cte64o8u7
11 Jan 24
A method of computational modeling to predict stability of a lyophilized drug product includes receiving model parameters describing a virtual cake, a virtual vial, a virtual stopper, and a virtual ambient environment.
Ron Christopher Kelly, Mary Chaves, Marc A. Caporini, Fabrice Schlegel
Filed: 30 Aug 21
Design
ahfhxiknv46dk3l4yktzjp4a2s1gz7hff1kbzfhtmsw8p
9 Jan 24
Emil Finkelstein, Kasper Friis, Lars Eilertsen
Filed: 30 Sep 19
Utility
cpo3rlhscfrm2orlujfr7u5d2sk3z86060ehjdponzk2ofmn9a06hgbma
9 Jan 24
Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Darren J. McMurtrie, Ryan J. Scamp, Ju Yang, Yibin Zeng, Penglie Zhang
Filed: 15 Oct 20
Utility
ubt0vtyh4rjsgr1i4i82gz2yyygk8zn3nr8u3ys9v1ccrupo5tswryj1
9 Jan 24
The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin.
William Christian Fanslow, III, Carl Kozlosky, Jean Gudas
Filed: 6 Jan 21
Utility
slkdrmwlirduqjgewe4igbm8v7 3zjix1he1
4 Jan 24
KYLE D. BAUCOM, MICHAEL T. CORBETT, SHENG CUI, NEIL F. LANGILLE, ANDREAS RENE ROTHELI, ROBERTO PROFETA, AUSTIN G. SMITH
Filed: 23 Nov 21
Utility
wfgye0yodn97m53d13godvthdvyhoyzmi02cbdxim
4 Jan 24
The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic.
Timothy RILEY, Fernando GARCES, Zhulun WANG, Bram Estes, Darren L. Bates
Filed: 9 Nov 21
Utility
2psj66k8v7zzxlr4ubd8bb1r3rsl63pi756b4dgxdlzmwr0
4 Jan 24
Anti-Folate Receptor Alpha (FOLR1) heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of Folate Receptor Alpha (FOLR1).
Brian Avanzino, Katherine Harris, Hannes Kehm, Nathan Trinklein
Filed: 17 Nov 21
Utility
pnluhqu7udnpq8xbdp9ryyo d12k3n8q9h88l7qcbcbekvb2kh1whw
4 Jan 24
Systems and methods of using a surrogate machine learning model, based on a CFD model, to predict the mixing quality in steady state mixing tanks are provided.
Emad Ghadirian Hoseinabadi, William Leigh Johnson
Filed: 29 Sep 21